Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
irodanoprost
- Development stage
- Unknown
- Lead developer
- Mesentech
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
Irodanoprost (MES1022) is a bone-targeted prodrug of a selective prostaglandin E2 receptor 4 (EP4) agonist developed by Mesentech. It consists of a potent EP4-selective agonist (MES1002) reversibly conjugated via a hydrolyzable ester linker to a bisphosphonate-based bone-binding moiety. This tissue-targeting design allows the drug to selectively distribute to calcium-rich tissues, such as bone and damaged myofibers, minimizing systemic exposure and off-target side effects. Upon esterase-mediated hydrolysis, the active EP4 agonist moiety is released. Irodanoprost is being developed for the treatment of bone fractures, osteoporosis, osteogenesis imperfecta, and muscular dystrophies, including Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD).
- Other names
- IROD
02
Targets
PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on irodanoprost.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on irodanoprost.